Clinical trials: Recurrent Ovarian Cancer
Ovarian Cancer
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
This research is being done to find out if Carboplatin and Taxane works better alone or when given with an experimental drug called MORAb-003(farletuzumab) in subjects with first platinum sensitive relapsed ovarian cancer.
- Trial name
- NCT00849667
- Testing
- Farletuzumab, Carboplatin, Taxane
- Where
- 375 sites in United States, Argentina and 28 more
- Volunteers
- 1,100 people
- Sponsor
- Morphotek
Ovarian Neoplasms
A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer
The primary objective of this study is to estimate the Progression Free Survival Rates (PFS) of patients with relapsed ovarian cancer after 9 months of continuous treatment with either BIBF 1120 or matching placebo.
- Trial name
- NCT00710762
- Testing
- BIBF1120
- Where
- 11 sites in United Kingdom
- Volunteers
- 89 people
- Sponsor
- Boehringer Ingelheim
Ovarian Cancer, Fallopian Tube Cancer
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
This research study is studying the combination of Pegylated Liposomal Doxorubicin (PLD) and Pembrolizumab as a possible treatment for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer that is resistant to platinum therapy.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT02865811
- Testing
- Pembrolizumab, Pegylated Liposomal Doxorubicin (PLD)
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Dana-Farber Cancer Institute
Malignant Ovarian Clear Cell Tumor, Recurrent Ovarian Carcinoma
Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer
This phase II trial studies how well pembrolizumab and epacadostat work in treating patients with ovarian clear cell carcinoma that has come back (recurrent), remains despite treatment (persistent), or is growing, spreading, or…
- Trial name
- NCT03602586
- Testing
- Epacadostat, Pembrolizumab
- Where
- 363 sites in United States, Puerto Rico
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple negative breast cancer…
- Trial name
- NCT03330405
- Testing
- Avelumab Phase 1b, Talazoparib Phase 1b, Avelumab Phase 2
- Where
- 66 sites in United States, Australia and 7 more
- Volunteers
- 223 people
- Sponsor
- Pfizer
Adult Angiosarcoma, Adult Epithelioid Sarcoma
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
This phase II trial is studying how well sorafenib works in treating patients with metastatic, locally advanced, or recurrent sarcoma.
- Conditions
- Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Leiomyosarcoma, Adult Malignant Fibrous Histiocytoma
- Trial name
- NCT00245102
- Testing
- sorafenib tosylate
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
Gleevec Study for Patients With Ovarian Cancer
Primary Objectives: 1. To determine the efficacy of Gleevec in patients with recurrent platinum-resistant, taxane-resistant epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer whose tumor expresses…
- Trial name
- NCT00510653
- Testing
- Imatinib Mesylate
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Granulosa-Stromal Tumor, Ovarian Granulosa Cell Tumor
Nirogacestat in Ovarian Granulosa Cell Tumors
This phase 2 clinical trial will study the effectiveness of nirogacestat in ovarian granulosa cell tumors (OvGCTs). Nirogacestat is a gamma secretase inhibitor (GSI) which is hypothesized to decrease the growth and activity of…
- Conditions
- Ovarian Granulosa-Stromal Tumor, Ovarian Granulosa Cell Tumor, Ovarian Cancer
- Trial name
- NCT05348356
- Testing
- Nirogacestat
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 53 people
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
To determine whether the combination of MM-121 plus paclitaxel is more effective than paclitaxel alone
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT01447706
- Testing
- MM-121, Paclitaxel
- Where
- 10 sites in United States
- Volunteers
- 223 people
- Sponsor
- Merrimack Pharmaceuticals
Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase I trial studies the side effects and best dose of gemcitabine hydrochloride and berzosertib when given together with carboplatin in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has…
- Conditions
- Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Ovarian Endometrioid Tumor
- Trial name
- NCT02627443
- Testing
- Berzosertib, Carboplatin, Gemcitabine Hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors
This phase II trial studies how well belinostat works in treating patients with ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer that have spread to other places in the body or ovarian low malignant…
- Conditions
- Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor, Recurrent Ovarian Carcinoma
- Trial name
- NCT00301756
- Testing
- Belinostat, Laboratory Biomarker Analysis
- Where
- 4 sites in Canada
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Fallopian Tube Cancer
GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer
Granulocyte macrophage colony-stimulating factor (GM-CSF) is an immunostimulant and preliminary data suggests it may change the natural history of prostate cancer and melanoma.
- Trial name
- NCT00157573
- Testing
- GM-CSF, sargramostim
- Volunteers
- 72 people
- Sponsor
- Massachusetts General Hospital
Ovarian Cancer
Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
RATIONALE: Estrogen can cause the growth of ovarian epithelial cancer cells. Hormone therapy using fulvestrant may fight ovarian cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00617188
- Testing
- Fulvestrant
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well dasatinib works in treating patients with persistent or recurrent ovarian epithelial…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT00671788
- Testing
- Dasatinib, Laboratory Biomarker Analysis
- Where
- 20 sites in United States
- Volunteers
- 35 people
- Sponsor
- Gynecologic Oncology Group
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This phase II trial is studying the side effects and how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, or…
- Conditions
- Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT00499252
- Testing
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation
- Where
- 20 sites in United States
- Volunteers
- 51 people
- Sponsor
- Gynecologic Oncology Group
Epithelial Ovarian Cancer, Fallopian Tube Cancer
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
The purpose of this study is to compare the overall survival of patients treated with VTX-2337 + pegylated liposomal doxorubicin (PLD) versus those treated with PLD alone in women with recurrent or persistent, epithelial ovarian…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01666444
- Testing
- pegylated liposomal doxorubicin (PLD), VTX-2337
- Where
- 136 sites in United States
- Volunteers
- 297 people
- Sponsor
- Celgene
Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
This phase II trial is studying how well giving cisplatin together with flavopiridol works in treating patients with advanced ovarian epithelial cancer or primary peritoneal cancer.
- Conditions
- Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Primary Peritoneal Cavity Cancer
- Trial name
- NCT00083122
- Testing
- cisplatin, alvocidib, cisplatin/flavopiridol
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Cancer, Primary Peritoneal Serous Adenocarcinoma
AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
This phase II trial is studying how well AZD2171 works in treating patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Serous Adenocarcinoma, Recurrent Ovarian Epithelial Cancer, Stage I Ovarian Epithelial Cancer
- Trial name
- NCT00275028
- Testing
- cediranib maleate
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Salvage Ovarian FANG™ Vaccine + Bevacizumab
This is a Phase II study of Vigil™ autologous tumor cell vaccine integrated with bevacizumab. All patients will have had Vigil™ prepared and stored from initial primary surgical debulking.
- Trial name
- NCT01551745
- Testing
- Vigil™ Vaccine, Bevacizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Gradalis, Inc.
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
Phase II trial to study the effectiveness of gemcitabine hydrochloride and tanespimycin in treating patients who have recurrent advanced ovarian epithelial or primary peritoneal cavity cancer.
- Conditions
- Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
- Trial name
- NCT00093496
- Testing
- gemcitabine hydrochloride, tanespimycin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)